Views & Analysis VPAS: Achievement so far on objectives for the economy and i... In the third part of this series taking stock of
Views & Analysis VPAS: Achievements so far on affordability In the second part of this series taking stock of
Views & Analysis VPAS: Achievement so far on objectives for patients The UK has a voluntary agreement that was struck by the government and NHS England (now referred to as NHSE&I) with the Association of the British Pharmaceutical Industry (ABPI) in 2018
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.